Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

WINT - WINDTREE THERAPEUTICS INC /DE/


IEX Last Trade
3.32
0   0%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%

$3.32
-3.00
9.37%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
6%
Profitability 1%
Dept financing 22%
Liquidity 35%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
-41.60%
3 Months
-90.03%
6 Months
-90.41%
1 Year
-55.48%
2 Year
-96.01%
Key data
Stock price
$3.32
P/E Ratio 
0.00
DAY RANGE
$0.32 - $3.32
EPS 
$0.00
52 WEEK RANGE
$0.34 - $14.75
52 WEEK CHANGE
-$55.47
MARKET CAP 
4.800 M
YIELD 
N/A
SHARES OUTSTANDING 
591.909 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$492,055
AVERAGE 30 VOLUME 
$1,199,122
Company detail
CEO: Craig E. Fraser
Region: US
Website: windtreetx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Windtree Therapeutics, Inc. focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trials for heart failure, and AEROSURF, an aerosolized KL4 surfactant.

Recent news